International Journal of Drug Policy
Volume 21, Issue 1 , Pages 70-76 , January 2010

A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility

Received 2 June 2008 ,Revised 27 January 2009 ,Accepted 27 March 2009.

References 

  1. Albert T, Williams G. The economic burden of HIV/AIDS in Canada. Ottawa, ON: Canadian Policy Research Networks; 1998;
  2. Belenko S, Patapis N, French MT. Economic benefits of drug treatment: A critical review of the evidence for policy makers. Philadelphia, PA: Treatment Research Institute, University of Pennsylvania; 2005;
  3. British Columbia Coroners Service (2008). British Columbia Coroners Service, Vancouver, Canada. Retrieved 01 February 2008 from http://www.pssg.gov.bc.ca/coroners/.
  4. Buxton J. Vancouver drug use epidemiology: Site report for the Canadian community epidemiology network on drug use. Ottawa, ON: Canadian Community Epidemiology Network on Drug Use, Canadian Centre on Substance Abuse; 2008;
  5. CBC News (2003). Vancouver's heroin users get safe-injection site, Vancouver, Canada. Retrieved 31 March 2008 from http://www.cbc.ca/news/story/2003/09/15/safe_injection030915.html.
  6. Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, et al. Distribution of health care expenditures for HIV-infected patients. Clinical Infectious Diseases. 2006;42:1003–1010
  7. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine, and alcohol combinations in accidental drug overdose deaths in New York City 1990–98. Addiction. 2003;98:739–747
  8. Cohen MA, Rust RT, Steen S, Tidd ST. Willingness-to-pay for crime control programs. Criminology. 2004;42:89–109
  9. CTV News (2008). Experts table findings on drug-injection site, Vancouver, Canada. Retrieved 12 April 2008 from http://www.ctv.ca.
  10. Davidson PJ, McLean RL, Kral AH, Gleghorn AA, Edlin BR, Moss AR. Fatal heroin-related overdose in San Francisco, 1997–2000: A case for targeted intervention. Journal of Urban Health. 2003;80:261–273
  11. Des Jarlais DC, Friedman SR, Choopanya K, Vanichsenis S, Ward TP. International epidemiology among injecting drug users. AIDS. 1992;6:1053–1068
  12. Des Jarlais DC, Marmor M, Paone D, Titus S, Shi Q, Perlis T, et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet. 1996;348:987–991
  13. Frei A, Greiner R-A, Mehnert A, Dinkel R. Socioeconomic evaluation of heroin maintenance treatment final report. In:  Gutzwiller F,  Steffen T editor. Cost-benefit analysis of heroin maintenance treatment, medical prescription of narcotics. Vol. 2:Basel: Karger Verlag; 2000;p. 37–133
  14. Gold M, Gafni A, Nelligan P, Millson P. Needle exchange programs: An economic evaluation of a local experience. Canadian Medical Association Journal. 1997;157:255–262
  15. Grover SA, Gilmore N, Tsoukas C, Falutz J, Sewitch M, Fakhry R. A prospective study of direct health care costs of HIV infected adults in Canada [abstract PO-D28-4226]. International Conference on AIDS. 1993;9:922
  16. Health Canada (2008). Expert Panel Report on Supervised Injection Site Released, Ottawa, Canada. Retrieved 23 April 208 from http://www.hc-sc.gc.ca/ahc-asc/media/nr-cp/2008/2008_57_e.html.
  17. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1997;16:55–61
  18. Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 1998;18(Suppl. 1):S133–S138
  19. Jacobs P, Calder P, Taylor M, Houston S, Saunders LD, Albert T. Cost effectiveness of Streetworks’ needle exchange program of Edmonton. Canadian Journal of Public Health. 1999;90:168–171
  20. Kaplan EH, O’Keefe E. Let the needles to the talking! Evaluating the New Haven needle exchange. Interfaces. 1993;23:7–26
  21. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005;366:316–318
  22. Kerr T, Tyndall M, Li K, Montaner JS, Wood E. Potential use of safer injecting facilities among injection drug users in Vancouver's downtown eastside. Canadian Medical Association Journal. 2005;169:759–763
  23. Kerr T, Stoltz J, Tyndall M, Li K, Zhang R, Montaner J, et al. Impact of a medically supervised safer injection facility on community drug use patterns: A before and after study. British Medical Journal. 2006;332:220–222
  24. Kerr T, Tyndall MW, Lai C, Montaner JSG, Wood E. Drug-related overdoses within a medically supervised safer injection facility. International Journal of Drug Policy. 2006;17:436–441
  25. Kimber J, Dolan K, van Beek I, Hedrich D, Zurhold H. Drug consumption facilities: An update since 2000. Drug and Alcohol Review. 2003;22:227–233
  26. Kimber J, Dolan K, Wodak A. A survey of drug consumption rooms: Service delivery and perceived public health and amenity impact. Drug and Alcohol Review. 2005;24:21–24
  27. Kleinig J. Thinking ethically about needle and syringe programs. Substance Use and Misuse. 2006;41:815–825
  28. Laufer FN. Cost-effectiveness of syringe exchanges as an HIV prevention strategy. Journal of Acquired Immune Deficiency Syndromes. 2001;28:273–278
  29. Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview. International Journal of Drug Policy. 2007;18(4):255–261
  30. Lurie P, Reingold AL, Bowser B, Chen D, Foley J, Guydish J, et al. The public health impact of needle exchange programs in the United States and abroad: Summary conclusions and recommendations. Berkeley, CA: School of Public Health, University of California; 1993;
  31. MSIC Evaluation Committee (2003). Final report on the evaluation of the Sydney Medically Supervised Injecting Centre. Sydney: Authors.
  32. McClean ME. Vancouver drug use epidemiology–2001: Vancouver and BC Site Report for the Canadian Community Epidemiology Network on Drug Use. Vancouver, BC: Vancouver–Richmond Health Board; 2002;
  33. Miller TR, Cohen MA, Wiersema B (1996). Victim costs and consequences: A new look. Research report. NCJ 155282. Washington, DC: U.S. Department of Justice, National Institute of Justice.
  34. Petrar S, Kerr T, Tyndall MW, Zhang R, Montaner JSG, Wood E. Injection drug users’ perceptions regarding use of a medically supervised safer injection facility. Addictive Behaviors. 2007;32:1088–1093
  35. Pinkerton SD, Holtgrave DR. Assessing the cost-effectiveness of HIV prevention interventions: A primer. In:  Holtgrave DR editors. Handbook of economic evaluation of HIV programs. New York, NY: Plenum; 1998;p. 33–43
  36. Rehm J, Ballunas D, Brochu S, Fischer B, Gnam W, Patra J, et al. The costs of substance abuse in Canada 2002, highlights. Ottawa, ON: Canadian Centre on Substance Abuse; 2006;
  37. Siegel JE, Weinstein MC, Fineberg HV. Bleach programs for preventing AIDS among IV drug users: Modelling the impact of HIV prevalence. American Journal of Public Health. 1991;81:1273–1279
  38. Single E, Robson L, Xie X, Rehm J. The costs of substance abuse in Canada 1992, highlights. Ottawa, ON: Canadian Centre on Substance Abuse; 1996;
  39. Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887–893
  40. Tyndall MW, Kerr T, Zhang R, King E, Montaner JG, Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug and Alcohol Dependence. 2006;83:193–198
  41. Tyndall MW, Wood E, Zhang R, Lai C, Montaner JSG, Kerr T. HIV seroprevalence along participants of a supervised injection facility in Vancouver, Canada. Harm Reduction Journal. 2006;3:36–40
  42. Vancouver Coastal Health (2007). Insite–Supervised Injection Site–Health Services–Vancouver Coastal Health, Vancouver, Canada. Retrieved 01 December 2007 from http://www.vch.ca/sis/.
  43. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. Public Health Reports. 1998;113(Suppl. 1):75–80
  44. Watters J, Estilo M, Clark G, Lorvick J. Syringe and needle exchange as HIV/AIDS prevention for injection drug users. Journal of the American Medical Association. 1994;271:115–120
  45. Wood E, Tyndall MW, Spittal PM, Li K, Kerr T, Hogg RS, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: Could safer injecting rooms help?. Canadian Medical Association Journal. 2001;165:405–410
  46. Wood E, Tyndall MW, Stoltz J, Small W, Lloyd-Smith E, Zhang R, et al. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. American Journal of Infectious Diseases. 2005;1:50–54
  47. Wood E, Tyndall MW, Zhang R, Stoltz J, Lai C, Montaner JSG, et al. Attendance of supervised injecting facilities and use of detoxification services. New England Journal of Medicine. 2006;354:2512–2514

PII: S0955-3959(09)00060-7

doi: 10.1016/j.drugpo.2009.03.004

International Journal of Drug Policy
Volume 21, Issue 1 , Pages 70-76 , January 2010

Article Tools